- Home
- ACIU vs GHI Comparison
ACIU vs GHI Comparison
Compare ACIU & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- GHI
- Stock Information
- Founded
- ACIU 2003
- GHI 1998
- Country
- ACIU Switzerland
- GHI United States
- Employees
- ACIU N/A
- GHI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- GHI Finance: Consumer Services
- Sector
- ACIU Health Care
- GHI Finance
- Exchange
- ACIU Nasdaq
- GHI Nasdaq
- Market Cap
- ACIU 332.4M
- GHI 251.4M
- IPO Year
- ACIU 2016
- GHI N/A
- Fundamental
- Price
- ACIU $2.66
- GHI $10.56
- Analyst Decision
- ACIU Strong Buy
- GHI Strong Buy
- Analyst Count
- ACIU 2
- GHI 4
- Target Price
- ACIU $12.00
- GHI $17.50
- AVG Volume (30 Days)
- ACIU 132.5K
- GHI 126.6K
- Earning Date
- ACIU 11-05-2024
- GHI 02-20-2025
- Dividend Yield
- ACIU N/A
- GHI 14.03%
- EPS Growth
- ACIU N/A
- GHI N/A
- EPS
- ACIU N/A
- GHI 0.61
- Revenue
- ACIU $48,505,404.00
- GHI $34,307,528.00
- Revenue This Year
- ACIU $85.33
- GHI N/A
- Revenue Next Year
- ACIU $80.69
- GHI $10.35
- P/E Ratio
- ACIU N/A
- GHI $17.20
- Revenue Growth
- ACIU 4097200.00
- GHI 28.98
- 52 Week Low
- ACIU $2.25
- GHI $10.32
- 52 Week High
- ACIU $5.14
- GHI $17.43
- Technical
- Relative Strength Index (RSI)
- ACIU 27.22
- GHI 38.61
- Support Level
- ACIU $2.63
- GHI $10.32
- Resistance Level
- ACIU $3.07
- GHI $11.05
- Average True Range (ATR)
- ACIU 0.15
- GHI 0.39
- MACD
- ACIU -0.04
- GHI 0.01
- Stochastic Oscillator
- ACIU 8.96
- GHI 27.85
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.